4 completed, 2 unknown, 1 terminated. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults MDI-1228_mesylate Ophthalmic Solution, Placebo - Allergic Conjunctivitis | Phase 1 | Completed | Shanghai Medinno Pharmaceutical Technology Co., Ltd. | 40 | 2023-10-06 | 2024-07-09 |
| Airway Immune Response to Allergens (Use Lay Language Here) Segmental allergen challenge - Allergic Asthma, Allergy to Cats | Phase 1 | Unknown | JOSALYN CHO | 12 | 2021-10-28 | 2023-08-31 |
| A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 1 / Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 52 | 2018-09-08 | 2025-04-08 |
| Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections Dose Level 1, Dose Level 2, Placebo - Allergic Conjunctivitis, Allergic Rhinitis | Phase 1 | Terminated | Woodmont Pharmaceuticals, Inc. | 2 | 2017-03-30 | 2018-02-26 |
| Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis XmAb7195, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 1 | Completed | Xencor, Inc. | 72 | 2014-05-01 | 2017-01-24 |
| The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions Allergen(Tree, Grass, Weeds) - Allergic Rhinitis, Asthma | Phase 1 / Phase 2 | Unknown | University Hospitals Cleveland Medical Center | 245 | 2013-04-01 | 2013-06-17 |
| Safety and Comfort of AL-4943A Ophthalmic Solution Olopatadine hydrochloride ophthalmic solution, 0.7%, Olopatadine hydrochloride ophthalmic solution vehicle, Ketotifen fumarate ophthalmic solution, 0.025% - Allergic Conjunctivitis | Phase 1 | Completed | Alcon Research | 50 | 2011-04-01 | 2015-03-03 |
Conjunctivitis, Allergic (7) · Rhinitis, Allergic (4) · Asthma (2) · Dermatitis, Atopic (1) · Dust Mite Allergy (1) · Hypersensitivity (1)
Conjunctival Diseases (7) · Conjunctivitis (7) · Eye Diseases (7) · Hypersensitivity, Immediate (7) · Immune System Diseases (7) · Hypersensitivity (6) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4) · Rhinitis (4) · Bronchial Diseases (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Olopatadine Hydrochloride (1) · ketotifen fumarate ophthalmic solution (1) · nabiximols (1)
Alcon Research (1) · Aldeyra Therapeutics, Inc. (1) · JOSALYN CHO (1) · Shanghai Medinno Pharmaceutical Technology Co., Ltd. (1) · University Hospitals Cleveland Medical Center (1) · Woodmont Pharmaceuticals, Inc. (1) · Xencor, Inc. (1)
United States (5) · Australia (1)
Abhijit Narvekar, MS, MBBS (1) · Devi K Jhaveri, D.O. (1) · Emily Schoemmell (1) · Haig Tcheurekdjian, M.D. (1) · Josalyn L Cho, MD (1) · Liang Lu, PhD (1) · Ronald Goldwater, MD (1) · Sepehr Shakib, PhD (1)